Oncopeptides Dirección

Dirección controles de criterios 2/4

El CEO de Oncopeptides es Sofia Heigis , nombrado en Aug 2023, tiene una permanencia de 1.25 años. compensación anual total es SEK3.18M, compuesta por 55.3% salario y 44.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.009% de las acciones de la empresa, por valor de SEK30.87K. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 7.1 años, respectivamente.

Información clave

Sofia Heigis

Chief Executive Officer (CEO)

SEK 3.2m

Compensación total

Porcentaje del salario del CEO	55.3%
Permanencia del CEO	1.3yrs
Participación del CEO	0.009%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	7.1yrs

Actualizaciones recientes de la dirección

Recent updates

An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Jun 18

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sofia Heigis en comparación con los beneficios de Oncopeptides?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-SEK 282m
Jun 30 2024	n/a	n/a	-SEK 263m
Mar 31 2024	n/a	n/a	-SEK 246m
Dec 31 2023	SEK 3m	SEK 2m	-SEK 249m

Compensación vs. Mercado: La compensación total ($USD287.33K) de Sofia está en línea con el promedio de empresas de tamaño similar en el mercado Swedish ($USD235.43K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Sofia con los resultados de la empresa.

CEO

Sofia Heigis (44 yo)

1.3yrs

Permanencia

SEK 3,180,000

Compensación

Ms. Sofia Heigis, M.sc, was Chief Commercial Officer and Managing Director of Germany at Oncopeptides AB (publ) since 2022 until 07 August 2023 and also serves as its CEO since 07 August 2023. Ms. Heigis j...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sofia Heigis	Chief Executive Officer	1.3yrs	SEK 3.18m	0.0093% SEK 30.9k
Jakob Lindberg	Chief Scientific Officer	1.8yrs	SEK 4.84m	0.40% SEK 1.3m
Rolf Larsson	Founder	no data	sin datos	sin datos
Rolf Lewensohn	Founder	no data	sin datos	sin datos
Joachim Gullbo	Founder	no data	sin datos	sin datos
Kristina Luthman	Founder	no data	sin datos	sin datos
Hans Ehrsson	Founder	no data	sin datos	sin datos
Peter Nygren	Founder	no data	sin datos	sin datos
Henrik Bergentoft	Chief Financial Officer	less than a year	sin datos	sin datos
Eva Nordström	COO & Deputy MD	4.8yrs	sin datos	0.056% SEK 184.6k
David Augustsson	Director of IR & Communications	1.8yrs	sin datos	sin datos
Sara Svardgren	Head of Human Resources	6.5yrs	sin datos	0.000040% SEK 132.2

1.8yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ONCO no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Per Wold-Olsen	Independent Chairman of the Board	6.5yrs	SEK 1.63m	0.23% SEK 764.3k
Per Anders Samuelsson	Independent Director	12.8yrs	SEK 355.00k	sin datos
Cecilia Wennborg	Independent Director	7.8yrs	SEK 682.50k	0.026% SEK 84.6k
Lori Kunkel	Member of Clinical Advisory Board	no data	sin datos	sin datos
Jarl Jungnelius	Independent Director	13.6yrs	SEK 627.50k	0.047% SEK 155.2k
Brian Stuglik	Independent Director	6.5yrs	SEK 755.00k	sin datos
Christian Jacques	Member of Clinical Advisory Board	no data	sin datos	sin datos
Jennifer Jackson	Independent Director	5.9yrs	SEK 755.00k	sin datos
Axel Glasmacher	Member of Clinical Advisory Board	no data	sin datos	sin datos
Paul Richardson	Member of Clinical Advisory Board	no data	sin datos	sin datos

7.1yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de ONCO se considera experimentada (7.1 años de antigüedad promedio).

Oncopeptides Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Recent updates

Consensus revenue estimates decrease by 19%, EPS upgraded

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.45 loss in 3Q 2023)

New minor risk - Share price stability

Consensus revenue estimates decrease by 34%, EPS upgraded

Price target decreased by 29% to kr4.33

Second quarter 2024 earnings released: kr0.48 loss per share (vs kr0.60 loss in 2Q 2023)

Consensus revenue estimates fall by 11%

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.

An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Consensus EPS estimates fall by 34%, revenue upgraded

First quarter 2024 earnings released: kr0.75 loss per share (vs kr0.75 loss in 1Q 2023)

Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress

New major risk - Shareholder dilution

Price target decreased by 7.2% to kr6.40

Consensus EPS estimates fall by 38%

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely

New major risk - Financial position

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Oncopeptides Selects to Present Additional Data from Ocean Study

Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?

Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results

Consensus revenue estimates increase by 47%

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Consensus revenue estimates decrease by 11%, EPS upgraded

No longer forecast to breakeven

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023

Full year 2022 earnings released: kr4.11 loss per share (vs kr19.00 loss in FY 2021)

Forecast to breakeven in 2024

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Announces Nomination Committee Appointments

Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Oncopeptides Provides Update on Pepaxto US Marketing Authorization

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Price target decreased to kr22.50

Consensus revenue estimates fall by 76%

Insufficient new directors

Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk

Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe

Forecast to breakeven in 2024

Oncopeptides AB (publ), Annual General Meeting, May 25, 2023

Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study

Consensus revenue estimates fall by 30%

Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market

Consensus revenue estimates fall by 36%

Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC

Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma

European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma

Consensus revenue estimates increase by 243%

Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma

Consensus revenue estimates increase by 89%

Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use

Price target increased to kr11.15

Consensus forecasts updated